Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Other Accumulated Expenses (2017 - 2025)

Historic Other Accumulated Expenses for Arcus Biosciences (RCUS) over the last 9 years, with Q3 2025 value amounting to $141.0 million.

  • Arcus Biosciences' Other Accumulated Expenses rose 4536.08% to $141.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $141.0 million, marking a year-over-year increase of 4536.08%. This contributed to the annual value of $123.0 million for FY2024, which is 6184.21% up from last year.
  • According to the latest figures from Q3 2025, Arcus Biosciences' Other Accumulated Expenses is $141.0 million, which was up 4536.08% from $110.0 million recorded in Q2 2025.
  • Arcus Biosciences' Other Accumulated Expenses' 5-year high stood at $141.0 million during Q3 2025, with a 5-year trough of $23.0 million in Q1 2021.
  • For the 5-year period, Arcus Biosciences' Other Accumulated Expenses averaged around $69.1 million, with its median value being $65.0 million (2023).
  • Its Other Accumulated Expenses has fluctuated over the past 5 years, first skyrocketed by 23867.31% in 2021, then plummeted by 158.88% in 2022.
  • Over the past 5 years, Arcus Biosciences' Other Accumulated Expenses (Quarter) stood at $54.0 million in 2021, then skyrocketed by 40.74% to $76.0 million in 2022, then changed by 0.0% to $76.0 million in 2023, then surged by 61.84% to $123.0 million in 2024, then increased by 14.63% to $141.0 million in 2025.
  • Its last three reported values are $141.0 million in Q3 2025, $110.0 million for Q2 2025, and $98.0 million during Q1 2025.